CoChat

M1 Agonists for the Treatment of Alzheimer's Disease.: Novel Properties and Clinical Updatea

FISHER, A., HELDMAN, E., GURWITZ, D., HARING, R., KARTON, Y., MESHULAM, H., PITTEL, Z., MARCIANO, D., BRANDEIS, R., SADOT, E., BARG, Y., PINKAS‐KRAMARSKI, R., VOGEL, Z., GINZBURG, I., TREVES, T. A., VERCHOVSKY, R., KLIMOWSKY, S., KORCZYN, A.D. · 1996 · Annals of the New York Academy of Sciences
Cited by 76

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

The AF series compounds, AF102B and congeners of AF150(S), are functionally selective agonists for m1 muscarinic receptors (m1AChRs). This is shown in stable transfected CHO and PC12 cells (PC12M1) with m1‐m5AChRs and m1AChRs, respectively. AF102B and AF150(S) are partial agonists, but AF150, AF151, and AF151(S) are full agonists in stimulating phosphoinositides hydrolysis or arachidonic acid release in these cells. Yet, all these compounds behave as antagonists when compared with carbachol in elevating cAMP levels. In PC12M1 cells, unlike carbachol, the AF series compounds induce only minimal to moderate neurite outgrowth. Yet, these agonists synergize strongly with NGF, which by itself mediates only a mild response. Stimulation of m1AChRs by AF102B, AF150(S) and AF151(S) in PC12M1 cells enhances secretion of β/A4 amyloid precursor protein derivatives (APPs). The enhanced APPs secretion induced by AF102B is potentiated by NGF. AF102B also stimulates APPs secretion from rat cortical slices. Stimulation of m1AChR in PC12M1 cells with carbachol or AF102B decreases tau phosphorylation as indicated by specific tau‐1 mAb and alkaline phosphatase treatment. Due to the above mentioned properties m1 agonists may be of unique value in delaying the progression of Alzheimer's disease (AD). The AF series compounds show a wide safety margin and improve memory and learning deficits in animal models for AD. There is a dearth of clinical reports on m1 agonists. These include studies on AF102B and xanomeline, another m1 selective agonist. We tested AF102B in escalating doses of 20, 40, 60 mg, tid, po, (each dose for 2 weeks) for a total of 10 weeks. This was a single‐blind placebo‐controlled, parallel‐group study in patients with probable AD. AFl02B was signiticantly effective at 40 and 60 mg, tid in the ADAS, ADAS‐cognitive and ADAS‐word recognition scales.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1749-6632.1996.tb34418.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 76

Metadata

Authors
FISHER, A., HELDMAN, E., GURWITZ, D., HARING, R., KARTON, Y., MESHULAM, H., PITTEL, Z., MARCIANO, D., BRANDEIS, R., SADOT, E., BARG, Y., PINKAS‐KRAMARSKI, R., VOGEL, Z., GINZBURG, I., TREVES, T. A., VERCHOVSKY, R., KLIMOWSKY, S., & KORCZYN, A. D.
Venue
Annals of the New York Academy of Sciences
Publisher
Wiley
Published
1996-01
Volume
777
Issue
1
Pages
189-196
ISSN
  • 0077-8923 (ISSN-L)
  • 1749-6632
OpenAlex
W1615644378
Cited by
76
References
2
FWCI
3.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: M1 Agonists for the Treatment of Alzheimer's Disease.: Novel Properties and Clinical Updatea. https://app.cochat.ai/papers/10.1111/j.1749-6632.1996.tb34418.x
The paper
FISHER, A., HELDMAN, E., GURWITZ, D., HARING, R., KARTON, Y., MESHULAM, H., PITTEL, Z., MARCIANO, D., BRANDEIS, R., SADOT, E., BARG, Y., PINKAS‐KRAMARSKI, R., VOGEL, Z., GINZBURG, I., TREVES, T. A., VERCHOVSKY, R., KLIMOWSKY, S., & KORCZYN, A. D. (1996). M1 Agonists for the Treatment of Alzheimer's Disease.: Novel Properties and Clinical Updatea. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.1996.tb34418.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.